Could miRNA Signatures be Useful for Predicting Uterine Sarcoma and Carcinosarcoma Prognosis and Treatment?

Laura Gonzalez dos Anjos 1, Bruna Cristine de Almeida 1, Thais Gomes de Almeida 1,2, André Mourão Lavorato Rocha 3, Giovana De Nardo Maffazzioli 1, Fernando Augusto Soares 3,4,5, Isabela Werneck da Cunha 3,4,5, Edmund Chada Baracat 1 and Katia Candido Carvalho 1,*

1 Laboratório de Ginecologia Estrutural e Molecular (LIM 58), Disciplina de Ginecologia, Departamento de Obstetricia e Ginecologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, HCFMUSP, SP, BR Av. Dr Arnaldo 455, sala 4121, Cerqueira Cesar, São Paulo 05403-010, Brazil; lauragonzalezanjos@gmail.com (L.G.d.A.); bruc_10@hotmail.com (B.C.d.A.); tgalmeida.sp@gmail.com (T.G.d.A.); giovanamaffazzioli@hotmail.com (G.D.N.M.); edmund.baracat@hc.fm.usp.br (E.C.B.)
2 Instituto Brasileiro de Controle do Cancer, SP, BR Av. Alcântara Machado, 2576 Mooca, São Paulo 05403-010, Brazil
3 Hospital A C Camargo Cancer Center, SP, BR R. Tamandaré, 753 Liberdade, São Paulo 05403-010, Brazil; lavorato.andre@gmail.com (A.M.L.R.); fasoares@me.com (F.A.S.); iwerneck0210@gmail.com (I.W.d.C.)
4 Department of Pathology, Rede D’OR-São Luiz, Rua das Perobas, 344-Jabaquara, São Paulo 04321-120, Brazil
5 National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, SP, BR R. Tamandaré, 753 Liberdade, São Paulo 05403-010, Brazil
* Correspondence: carvalhokc@gmail.com; Tel.: +55-011-3061-7486

Received: 21 July 2018; Accepted: 4 September 2018; Published: 6 September 2018

Abstract: Changes in microRNA (miRNA) expression may lead to cancer development and/or contribute to its progression; however, their role in uterine sarcomas is poorly understood. Uterine sarcomas (US) belong to a rare class of heterogeneous tumors, representing about 1% of all gynecologic neoplasms. This study aimed to assess the expression profile of 84 cancer-related miRNAs and to evaluate their correlation with clinical pathological features. Eighty-two formalin-fixed paraffin-embedded (FFPE) samples were selected. In leiomyosarcoma (LMS), there was an association of lower cancer-specific survival (CSS) with the downregulation of miR-125a-5p and miR-10a-5p, and the upregulation of miR-196a-5p and miR-34c-5p. In carcinosarcoma (CS), lower CSS was associated with the upregulation of miR-184, and the downregulation of let-7b-5p and miR-124. In endometrial stromal sarcomas (ESS), the upregulation of miR-373-3p, miR-372-3p, and let-7b-5p, and the down-expression of let-7f-5p, miR-23-3p, and let-7b-5p were associated with lower CSS. Only miR-138-5p upregulation was associated with higher survival rates. miR-335-5p, miR-301a-3p, and miR-210-3p were more highly expressed in patients with tumor metastasis and relapse. miR-138-5p, miR-146b-5p, and miR-218-5p expression were associated with higher disease-free survival (DFS) in treated patients. These miRNAs represent potential prediction markers for prognosis and treatment response in these tumors.

Keywords: uterine sarcomas; carcinosarcoma; miRNA; oncomirs; miRNA expression

1. Introduction

Uterine sarcomas (US) belong to a rare class of heterogeneous tumors comprising 3–7% of all malignancies in the uterus, representing about 1% of all gynecologic tumors [1]. In 2018, the
American Cancer Society estimated 63,230 new cases of uterine body cancer in the United States, with 11,350 deaths estimated as being caused by these tumors [2].

Previously, the US were histologically classified into uterine carcinosarcoma (CS; also called malignant mixed Müllerian tumors (MMMT), uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), and undifferentiated sarcomas [1,3]. Recently, CS have been reclassified as a metaplastic form of endometrial carcinoma; however, this tumor is still included in several studies of mesenchymal tumors and in the 2014 World Health Organization (WHO) US classification [4]. Currently, mesenchymal tumors are divided into LMS (63%), ESS (21%; usually divided into low-grade (LG-ESS) and high grade (HG-ESS), adenosarcomas (ADS, 5%), high grade undifferentiated sarcomas (5%), and other rare subtypes [5]. Here, we included CS samples for comparison with sarcomas samples considering their mesenchymal component.

US are characterized by occurrences of rapid progression, with high rates of local recurrence and distant metastasis, and poor prognosis. The overall survival rate is less than 50% in two years, even when diagnosed early [4]. The high lethality and poor prognosis are the main challenges for the optimal treatment of these tumors [6,7]. Despite their clinical relevance, few studies have been developed with regards to the molecular features involved in USs' malignancy risk or biological behavior.

Epigenetic studies have demonstrated that microRNAs (miRNAs) are involved in multiple biological functions, including regulation of gene expression at the posttranscriptional level, cell proliferation, apoptosis, metabolism, angiogenesis, and others [8–10]. Thereby, miRNA differential expression caused by chromosomal alterations might lead to cancer development and/or its progression [10]. The molecular mechanism of miRNA and target gene interactions are not always clear, nor how altered miRNA patterns may directly cause cancer or be rather an indirect effect of changes in cellular phenotype. Nonetheless, miRNA expression patterns differ for specific tissues and differentiation states [11].

miRNA is a short non-coding RNA with around 19–27 nucleotides [12,13] that acts as a tumor suppressor (negatively regulating protein-coding oncosgenes) or as an oncomir (repressing known tumor suppressors) and can affect cancer phenotypes [14]. Moreover, several reports have identified miRNA expression profiles, such as tumor signatures [14].

This molecule can control tumor metastasis through the divergent or convergent regulation of signaling pathways. The prognostic capacity of these non-coding RNAs in predicting human metastatic outcomes suggests an important role in cancer progression [15]. The molecular mechanisms of miRNAs and their roles in the physiological and pathological processes, as well as their correlation with prognosis and treatment prediction in patients with uterine mesenchymal tumors and CS, are still unknown. Attempting to identify predictor biomarkers based on the miRNA expression profile for US diagnosis, prognosis, or treatment led to the present study being conceived. This study aims to evaluate the expression profile of 84 oncomir sequences and to assess their expression profile correlation with the clinical pathological features of patients with LMS, CS, ESS, and ADS.

2. Results

For formalin-fixed paraffin-embedded (FFPE) sample analysis, we distributed the uterine sarcomas in four groups: The LMS group was composed of 37 patients with ages ranging from 32 to 91 years old (mean age: 56 ± 14.80 years old; data represents the mean ± SD); the CS group was composed of 23 patients with ages ranging from 54 to 87 years old (mean age: 67.30 ± 9.397 years old); the ESS group had 18 patients with ages ranging from 27 to 82 years old (mean age: 55.61 ± 15.41 years old); and two patients were included in the ADS group with ages ranging from 68 to 72 years old (mean age: 70 ± 2.828 years old). The LMS and CS groups differ in the age mean ($p = 0.0048$).

Clinical and anatomopathological features of evaluated patients in the study are described in Tables 1 and 2.
### Table 1. Clinical pathological features of cancer patients (n = 80) *

| Variables            | Categories    | n (%)       |
|----------------------|---------------|-------------|
| **Age**              | ≥50 years     | 59 (74)     |
|                      | <50 years     | 21 (26)     |
|                      | N. A.         | 0 (0)       |
| **Main complaint**   | Bleeding      | 48 (60)     |
|                      | Pelvic Pain   | 18 (23)     |
|                      | N. A.         | 14 (17)     |
| **Menopause**        | Yes           | 54 (67)     |
|                      | No            | 11 (14)     |
|                      | N. A.         | 15 (19)     |
| **Contraceptive**    | Yes           | 3 (4)       |
|                      | No            | 42 (52)     |
|                      | N. A.         | 35 (44)     |
| **Hormone replacement therapy (HRT)** | Yes | 2 (3) |
|                      | No            | 49 (61)     |
|                      | N. A.         | 29 (36)     |
| **Smoking**          | Yes           | 3 (4)       |
|                      | No            | 30 (37)     |
|                      | N. A.         | 47 (59)     |
| **Surgical treatment** | Yes      | 78 (98)     |
|                      | No            | 2 (2)       |
| **Follow up**        | Average       | 36 months   |
|                      | Range         | 1 to 183 months |
| **Metastasis**       | Yes           | 52 (65)     |
|                      | No            | 21 (26)     |
|                      | N. A.         | 7 (9)       |
| **Death**            | Yes           | 55 (69)     |
|                      | Alive         | 15 (19)     |
|                      | N. A.         | 10 (12)     |

* N. A: not available.

### Table 2. Clinical and anatomopathological aspects according to the histological type of neoplasia (n = 80) *

| Variables        | Categories | LMS n (%) | CS n (%) | ESS n (%) | ADS n (%) |
|------------------|------------|-----------|----------|-----------|-----------|
| **Clinical Stage**| I          | 10 (27)   | 4 (17.4) | 7 (38.9)  | 2 (100)   |
|                  | II         | 10 (27)   | 2 (8.7)  | 3 (16.7)  | 0 (0)     |
|                  | III        | 12 (32.5)| 6 (26.1) | 1 (5.5)   | 0 (0)     |
|                  | IV         | 0 (0)     | 0 (0)    | 0 (0)     | 0 (0)     |
|                  | N. A.      | 0 (0)     | 0 (0)    | 0 (0)     | 0 (0)     |
| **Histological Grade** | High  | 27 (73) | 23 (100) | 13 (72.2) | 1 (50) |
|                  | Low        | 10 (27)   | 0 (0)    | 5 (27.8)  | 1 (50)    |
|                  | N. A.      | 0 (0)     | 0 (0)    | 0 (0)     | 0 (0)     |
| **Recurrence**   | No         | 6 (17)    | 8 (35)   | 3 (17)    | 1 (50)    |
|                  | Persistence| 12 (32)   | 6 (26)   | 7 (39)    | 0 (0)     |
|                  | Relapse    | 15 (40)   | 5 (22)   | 7 (39)    | 0 (0)     |
|                  | N. A.      | 4 (11)    | 4 (17)   | 1 (5)     | 1 (50)    |
| **Metastasis**   | Locoregional| 12 (5)  | 2 (9)    | 3 (17)    | 0 (0)     |
|                  | Distant    | 15 (55)   | 9 (39)   | 11 (61)   | 0 (0)     |
|                  | N. A.      | 10 (40)   | 12 (52)  | 4 (22)    | 2 (100)   |
| **Adjuvant Treatment** | No   | 10 (27)  | 5 (21.7) | 5 (27.8)  | 0 (0)     |
|                  | RT         | 11 (29.7)| 8 (34.8) | 6 (33.3)  | 2 (100)   |
|                  | CT         | 11 (29.7)| 3 (13.1) | 4 (22.2)  | 0 (0)     |
|                  | CT+RT      | 5 (13.6) | 7 (30.4) | 3 (16.7)  | 0 (0)     |
|                  | N. A.      | 0 (0)     | 0 (0)    | 0 (0)     | 0 (0)     |
| **Status**       | Alive      | 7 (18.9) | 3 (13)   | 4 (22.2)  | 1 (50)    |
|                  | Death      | 26 (70.3) | 16 (70)  | 13 (72.2) | 0 (0)     |
|                  | Loss of follow-up | 4 (10.8)  | 4 (17)  | 1 (5.6)  | 1 (50)    |
|                  | N. A.      | 0 (0)     | 0 (0)    | 0 (0)     | 0 (0)     |

RT: radiotherapy; CT: chemotherapy; LMS: uterine leiomyosarcoma; CS: carcinosarcoma; ESS: endometrial stromal sarcomas; ADS: adenosarcoma.
We performed a hierarchical clustering analysis of 84 miRNAs with an expression profile for each histological tumor group. Data analysis showed different expressions of 18 upregulated miRNAs in LMS samples, 22 in CS samples, 18 in ESS samples, and 15 in ADS samples. We found 6 downregulated miRNAs in cases of LMS, 9 in CS, 9 in ESS and 15 in ADS, using benign uterine samples as a reference for a normal gene expression profile (Figure 1).

Figure 1. Clustergram analysis showing the expression profile of 84 oncomirs accessed in uterine leiomyosarcoma (LMS); uterine carcinosarcoma CS, endometrial stromal sarcoma (ESS), and adenosarcoma (ADS)*, using benign uterine tissue (Ref) as a reference for a normal gene expression profile (fold change (FC) expression cut-off values of +2 and −2). *ADS was not part of the statistical or subsequent analyses.

Statistical analysis between the miRNA differential expressions and clinical pathological data of patients with LMS, CS and ESS showed that 59 miRNAs are significantly associated to clinical features. However, this analysis could not be performed given the limited number of samples in the ADS group. Among the significant associations found, we can highlight those related to the diagnosis,
prognosis, and treatment. Shifts in the molecules’ expression of miR-301a-3p, miR-29a-3p, miR-29b-3p, and miR-193b-3p and in the tumor suppressor family let-7, miR-7-5p, miR-96-5p, miR-23b-3p, and miR-335-5p were associated to recurrence, metastasis, stages, and high histological degree (Table 3).

**Table 3.** Association between the expression of the microRNAs (miRNAs) and the clinical pathological features (*n* = 80).

| Clinical Variable                  | LMS          | CS            | ESS           |
|-----------------------------------|--------------|---------------|---------------|
|                                   | miRNA        | p             | miRNA         | p             | miRNA         | p             |
| Age (over 50 years old)           | 220c-3p      | 0.049         | -             | -             | 142-5p        | 0.031         |
|                                   | 29a-3p       | 0.033         | -             | -             | 148b-5p       | 0.016         |
| Main complaint—Bleeding           | -            | -             | -             | -             | 214-3p        | 0.016         |
| Menopause                         | 148a-3p      | 0.022         | 30c-5p        | 0.001         | 335-5p        | 0.025         |
|                                   | 7-5p         | 0.023         | 148a-3p       | 0.004         | -             | -             |
|                                   | 32-5p        | 0.030         | 100-5p        | 0.034         | -             | -             |
|                                   | -            | -             | let-7-5p      | 0.001         | -             | -             |
| Oral contraceptive               | -            | -             | -             | -             | 132-3p        | 0.005         |
|                                   | -            | -             | -             | -             | 34c-5p        | 0.006         |
| HRT                               | -            | -             | -             | -             | 125a-5p       | 0.039         |
|                                   | -            | -             | -             | -             | 222-3p        | 0.039         |
|                                   | -            | -             | -             | -             | 205-5p        | 0.019         |
| Smoking                           | -            | -             | -             | -             | 27b-3p        | 0.018         |
|                                   | -            | -             | 125a-5p       | 0.011         | 143-3p        | 0.038         |
|                                   | -            | -             | 30c-5p        | 0.011         | -             | -             |
|                                   | -            | -             | 133b-5p       | 0.011         | -             | -             |
|                                   | -            | -             | let-7-5p      | 0.006         | -             | -             |
|                                   | -            | -             | 27b-3p        | 0.011         | -             | -             |
|                                   | -            | -             | 29a-3p        | 0.044         | -             | -             |
|                                   | -            | -             | let-7-5p      | 0.018         | -             | -             |
|                                   | -            | -             | 34a-5p        | 0.011         | -             | -             |
|                                   | -            | -             | 25-3p         | 0.007         | -             | -             |
|                                   | -            | -             | 125b-5p       | 0.028         | -             | -             |
|                                   | -            | -             | 23b-3p        | 0.028         | -             | -             |
|                                   | -            | -             | 335-5p        | 0.044         | -             | -             |
|                                   | -            | -             | 21-5p         | 0.029         | -             | -             |
| Patients who died                 | 96-3p        | 0.023         | 335-5p        | 0.050         | -             | -             |
|                                   | 132-3p       | 0.026         | 96-5p         | 0.008         | -             | -             |
|                                   | 183-5p       | 0.001         | 378a-3p       | 0.028         | -             | -             |
|                                   | 124-3p       | 0.024         | 123-5p        | 0.028         | -             | -             |
| Presence of relapse               | 148a-3p      | 0.021         | 130a-3p       | 0.046         | 301a-3p       | 0.041         |
|                                   | 29b-3p       | 0.008         | 183-5p        | 0.016         | -             | -             |
|                                   | 301a-3p      | 0.027         | 134-5p        | 0.040         | -             | -             |
|                                   | 29a-3p       | 0.040         | 7-5p          | 0.026         | -             | -             |
|                                   | 144-3p       | 0.020         | 128-3p        | 0.033         | -             | -             |
|                                   | -            | -             | 18a-5p        | 0.020         | -             | -             |
|                                   | -            | -             | 203a-3p       | 0.008         | -             | -             |
|                                   | -            | -             | 32-5p         | 0.008         | -             | -             |
|                                   | -            | -             | 127-5p        | 0.045         | -             | -             |
| Presence of metastasis            | 140-5p       | 0.002         | -             | -             | 193b-3p       | 0.015         |
|                                   | 193b-3p      | 0.002         | let-7-5p      | 0.034         | 210-3p        | 0.044         |
|                                   | -            | -             | 27b-3p        | 0.029         | -             | -             |
|                                   | -            | -             | 143-3p        | 0.004         | -             | -             |
|                                   | -            | -             | 125b-5p       | 0.025         | -             | -             |
| Stage I                           | -            | -             | -             | -             | -             | -             |
### Table 3. Cont.

| Clinical Variable       | LMS     | p     | CS     | p     | ESS     | p     |
|-------------------------|---------|-------|--------|-------|---------|-------|
|                         | miRNA   |       | miRNA  |       | miRNA   |       |
| Stage II                | -       | -     | 335-5p | a, s  | 218-5p  | a     |
|                         |         |       | 0.001  |       | 0.014   |       |
| Stage IV                | -       | -     | -      | -     | 7-5p    | b     |
|                         |         |       |        |       | 0.014   |       |
| High histological grade | let-7a-5p | 0.008 | 125a-5p | 0.047 | 222-3p  | 0.040 |
|                         | 148b-3p | 0.050 | 92a-3p | 0.029 | let-7b-5p | 0.009 |
|                         | 205-5p  | 0.010 | 20a-5p | 0.008 | 30c-5p  | 0.031 |
|                         | let-7g-5p | 0.005 | let-7c-5p | 0.029 | let-7e-5p | 0.014 |
|                         | let-7f-5p | 0.045 | 218-5p | 0.001 | 100-5p  | 0.044 |
|                         |         |       | 184     | a, *  |        | 0.001 |
|                         |         |       |        |       |        |       |

In order to analyze the cancer-specific survival (CSS) of patients, we evaluate each miRNA that presented association with any tumor type. For all statistical analyses, we consider significantly different expressed miRNAs that were higher than the cut-off of >+4 and <-4. This cut-off was established to increase the accuracy of the results and, increase the chances of a biological validation. Significant associations of the downregulation of miR-125a-5p and miR-10a-5 with a lower CSS were observed in LMS, whereas miR-196a-5p and miR-34c-5p upregulation were associated to low CSS (Figure 2).

For the CS patients, we found that three miRNAs (miR-184, let-7b-5p, and miR-124-3p) showed association with CSS (Figure 3). miR-184 upregulation and let-7b-5p and miR-124-3p down regulation showed association with a lower CSS.

The overall survival of ESS patients showed association with six miRNAs’ (let-7b-5p, miR-138-5p, miR-373-3p, miR-372-3p, let-7f-5p, and miR-23b-5p) differential gene expression. After that, the survival rates were assessed only for HG-ESS patients (12 cases) due to its poor prognosis and lower overall survival rates. A great number of ESS cases were present in our samples (18 samples), but six were classified as low histological grade and did not allow for correlation analysis between miRNA profile and survival rates (Figure 4). In these samples, miR-373-3p and miR-372-3p up-regulation showed correlation with a lower CSS, as well as let-7f-5p and miR-23b-3p downregulation. Only miR-138-5p upregulation was associated with higher survival.
Figure 2. Kaplan Meier curves and estimates of cancer-specific survival (CSS) associated with miRNA expression in LMS patients. (a) miR-196a-5p showed a strong association with CSS (n = 32) (p < 0.001). (b) Association of miR-34c-5p expression with CSS (n = 31) (p = 0.002). (c) miR-125a-5p expression associated with CSS (n = 32) (p = 0.010). (d) miR-10a-5p expression was associated with CSS (n = 32) (p = 0.017).

Figure 3. Cont.
The molecules that appeared significantly associated in this analysis presented a higher chemotherapy and/or radiotherapy, considering metastasis and/or relapse occurrence. Three miRNAs showed correlation with a lower CSS, as well as let-7f-5p and miR-23b-3p downregulation. Only miR-138-5p upregulation was associated with higher survival.

Three miRNAs (miR-184 and miR-124-3p showed associations with CSS \( (n = 19) \) \( (p = 0.016 \) and \( p = 0.038, \) respectively) in both cases; while let-7b-5p exhibited a strong association with CSS \( (n = 19) \) \( (p < 0.001) \).

The expression profiles of miR-184 and miR-124-3p showed associations with CSS \( (n = 19) \) \( (p = 0.038, \) respectively) in both cases; while let-7b-5p exhibited a strong association with CSS \( (p < 0.001) \). (e,f) let-7f-5p and miR-23b-3p expression were associated with CSS \( (p = 0.012) \).

We assessed the disease-free survival (DFS) in 60 patients who had undergone adjuvant treatment (chemotherapy and/or radiotherapy), considering metastasis and/or relapse occurrence. Three miRNAs (miR-335-5p, miR-301a-3p and miR-210-3p) presented differences of expression when we compared two groups of patients: those who had adjuvant treatment and developed metastasis or tumor recurrence (\( n = 41 \)) with patients who also had adjuvant treatment but did not develop metastasis or relapse (\( n = 13 \)) (Figure 5). The molecules that appeared significantly associated in this analysis presented a higher expression in patients with metastatic tumors or who presented recurrence (\( p < 0.05 \)).
Twenty-one LMS patients had metastasis and/or relapse and five did not show tumor progression. In the CS patients, nine presented metastasis and/or relapse, but in five patients, the tumor had not progressed. Almost all ESS patients \((n=13)\) had metastasis and/or relapse, whereas two patients did not have the tumor spread. In these 13 cases, four were classified as low-grade, where two of them had metastasis or relapse. All others were classified as high grade with presence of metastasis or relapse. One of two patients with ADS had tumor metastasis and/or relapse. In the association analysis of the miRNA expression and metastasis and/or relapse in LMS and CS patients, there was a significant differential expression of miR-335-5p \((p=0.015)\) and miR-301a-3p \((p=0.025)\) only in LMS. CS analysis was performed, but with no statistical significance. The reduced sample number \((n=2)\) was a limitation for the statistical analysis in ESS patients without metastasis and/or relapse (Figure 6).

We performed a correlation analysis with all tumor groups that showed a positive association between three miRNAs (miR-138-5p, miR-146-5p and miR-218-5p) with DFS (Table 4); of these, the miR-138-5p displayed a strong correlation with DFS \((p<0.001)\) (Figure 7). Figure 8 shows briefly the expression of the 48 miRNAs correlated to metastasis (or relapse), CSS, treatment response and DFS.

### Table 4. Correlation analysis between miRNA and DFS.

| miRNA     | r *  | p    |
|-----------|------|------|
| miR-146b-5p | 0.358 | 0.032 |
| miR-218-5p | 0.331 | 0.048 |
| miR-138-5p | 0.534 | <0.001 |

* Pearson correlation coefficient (r-value measures the intensity and direction of the linear connection between two quantitative variables).
In order to assess the miRNAs’ network of genetic interactions and their potential targets, the miR-146b-5p, miR-218-5p and miR-138-5p were selected based on their association with DFS in US and carcinomas patients who had undergone adjuvant treatment (Figures 9–11).

Through the bibliographic research of miRNAs validation studies with their respective target genes and with the aid of the miRTarBase platform (http://mirtarbase.mbc.nctu.edu.tw/php/index.php), the main interaction network among these molecules was established. Relevant interactions were found between the miR-146b-5p and the NFkB1 and CDKN1A genes. This miRNA was also indirectly correlated to the EGFR gene. miR-218-5p was directly associated to the CDKN1A gene, and indirectly to the SMO gene. Lastly, miR-138-5p was related to the IGF1R gene. Genes directly regulated for these miRNAs were related to transcriptional regulation, growth factors, cell cycle regulation and encoded protein transduces signals. These results are encouraging for future research aiming to discover the biological effects of these interactions.
Figure 9. Interaction network of miR-146b-5p. (a) The mRNA showed a strong modulation of NFKB1 and CDKN1A, and an indirect interaction with EGFR. (b) Molecular structure: pre-miRNA hairpin of miR-140b-5p, second structure of pre-miRNA, and, in red, mature sequence 9|UGAGAACUGAAUUCCAUAGGCU|30. (c–e) miRNA sequence of target interactions with NFKB1, CDKN1A and EGFR, respectively, showing the position in the gene sequence. Dark blue shows strong evidence (reporter assay, Western blot, qRT-PCR, or qPCR), and light blue shows other evidence.

Figure 10. Interaction network of miR-218-5p. (a) The mRNA showed a strong modulation of CDKN1A and an indirect interaction with SMO. (b) Molecular structure: pre-miRNA hairpin of miR-218-5p, second structure of pre-miRNA, and, in red, mature sequence 25|UUGUGCUUGAUCUAACCAUGU|45. (c,d) miRNA sequence of target interactions with CDKN1A and SMO, respectively, showing the position in the gene sequence. Dark blue shows strong evidence (reporter assay, Western blot, qRT-PCR, or qPCR), and light blue shows other evidence.
were associated with CSS in HG-ESS. Due to the limited number of ADS samples, survival analysis for this group was not performed. Although the mentioned miRNAs may represent potential prognostic biomarkers, future biological validations are necessary for their precise role establishment in the uterine tumors. To the best of our knowledge, there are no adequate biomarkers available yet for such as age, stage, tumor size, presence or absence of necrosis, and mitotic index [6] along with miRNA differential expression profiles might be important to determining these tumors’ prognoses. Here, we found miRNA expression profiles were associated with the CSS of patients. miR-196a-5p, miR-138-5p, miR-373-3p, miR-372-3p, let-7f-5p, and miR-23b-3p were associated with CSS in HG-ESS. Due to the limited number of ADS samples, survival analysis for this group was not performed. Although the mentioned miRNAs may represent potential prognostic biomarkers, future biological validations are necessary for their precise role establishment in the uterine tumors.

3. Discussion

This study corroborates the high-aggressive profile of US with a greater propensity to metastasize, as previously demonstrated in several studies [16–19]. These tumors are, therefore, associated with high rates of mortality. In the current study, 59% of evaluated patients were more than 50 years old at diagnosis. As seen in the literature [6,20,21], the majority of patients had abnormal vaginal bleeding, especially at the post-menopausal stage. Hysterectomy is considered the standard surgical treatment for US and CS [22,23], and was performed in 98% of patients. Sixty-five percent of patients were diagnosed with metastasis, with more than half (67.3%) spread out to distant organs. In addition, most patients died (70%). Naaman et al. [24] described that the US overall survival rate is low: 50–70% for patients with stage I, and 0–20% only for other stages.

Elucidating the role of miRNAs in tumor behavior and development was also an aim of the present study. In spite of the scarcity and the heterogeneity of these tumors, we attempted to find specific tumoral signatures. To the best of our knowledge, there are no adequate biomarkers available yet for the diagnosis or correct evaluation of these neoplasms. miRNAs have been studied in uterine tumors, and aberrant expression patterns were identified in several sarcoma types [25]. Clinical features such as age, stage, tumor size, presence or absence of necrosis, and mitotic index [6] along with miRNA differential expression profiles might be important to determining these tumors’ prognoses. Here, we found miRNA expression profiles were associated with the CSS of patients. miR-196a-5p, miR-34c-5p, miR-125a-5p, and miR-10a-5p expressions were associated with CSS in LMS women. Additionally, the miR-184, miR-124-3p and let-7b-5p showed an association between CSS and CS. Differential expressions of let-7b-5p, miR-138-5p, miR-373-3p, miR-372-3p, let-7f-5p, and miR-23b-3p were associated with CSS in HG-ESS. Due to the limited number of ADS samples, survival analysis for this group was not performed. Although the mentioned miRNAs may represent potential prognostic biomarkers, future biological validations are necessary for their precise role establishment in the uterine tumors.
Furthermore, associations between miRNA expression patterns with clinical features led us to a better understanding of how these markers are related to the greater or lesser survival rate of patients. In addition, our findings showed strong associations between miRNA expression (down or upregulated) and patients’ clinical features, such as recurrence, relapse, metastasis and survival rates. Basic miRNA expression profiling is proving to be clinically relevant to cancer diagnosis, progresses and outcome [11,26,27]. The association of miRNA expression levels with anatomopathological and clinical data may be relevant as a diagnostic biomarker for identifying or differentiate US.

Kowalewska et al. 2013 [28] evaluated the expression profile of miRNAs in LMS, ESS, CS, and ADS. Our study corroborates many of the differences in miRNA expression profiles found in this study. Both studies found differences in the expression of the miR-23, miR-1, let-7f, and let-7c in ESS in relation to benign samples. Another similar result was associated with mixed tumors. Both studies showed the downregulation of miR-1, let-7c, miR-133b, let-7b, miR-143, let-7a, let-7d, let-7e, let-7g, miR-222, let-7i, and miR-214 in relation to the benign tissue. The upregulation of the miR-206 was also observed in the two studies. The miR-206 has NOTCH3 as target gene. The pathogenic effects caused when the NOTCH signaling pathway is modified were already described in other sarcomas [28,29].

A recent molecular study analyzed 381 miRNAs in LMS and ESS, showing different expression in 94 miRNAs. After validation experiments, seven miRNAs (miR-15b, miR-21, miR-23b, miR-25, miR-145, miR-148b and miR-195) were upregulated in ESS when compared to primary LMS. Among these molecules, only the expression of miR-25 presented a similar profile in our analysis [30]. Changes in miR-25 expression have already been associated with lymph node metastasis in osteosarcoma [31].

Shi et al. 2009 [32] found a significant correlation between endogenous HMGA2 levels and let-7 expression in uterine LMS. In this study, it has been verified that treatment with exogenous let-7 significantly reduced cell proliferation through the repression of HMGA2. We evaluated the expression of eight molecules of the let-7 family and all were shown to be altered, mainly let-7a-5p (fold: −5.41).

All studies have found limitations in sample size, due to tumor rarity, but the observed similarities can be significant for future research. These differences may have occurred due to sample size differences, tumor heterogeneity and differences in the specific population.

Global gene expression patterns were compared in primary and metastatic LMS. The existence of a unique genetic signature was confirmed for these conditions. A high expression of TNNT1, FOLR3, TDO2, CRYM, GJA1, TSPAN10, THBS1, SGK1, SHMT1, EGR2 and AGT genes in metastasis were displayed [33]. Through interaction analysis of miRNA and their target genes in the data bank, we observed that many miRNAs analyzed in our study are associated with recurrence, relapse and metastasis, regulating mentioned genes from Davidson et al.’s [33] research. We found that miR-29b-3p and miR-29a-3p regulate SGK1; miR-335-5p, miR-125b-5p and miR-193b-5p regulate SHMT1; miR-130a-3p regulates GJA1; and miR-18a-5p and let-7i-5p regulate THBS1. This analysis indicates that the deregulation of these molecules can be associated with more aggressive tumor phenotypes.

Almost one-third of miRNAs located in a small region of chromosome 14q32 are significantly altered in CS tissues compared to benign endometrium [34]. Analogously to the study of Devor et al. [34], miR-127-5p, which is associated with the presence of recurrences in CS patients in our study, displayed expression alterations in this tumor type. Data indicate that a specific deregulation contributes to a unique histology and worse prognosis in CS.

In the ESS, the miR-210-3p seems to be specifically related to metastasis in our analysis. Our data revealed that the expression profile of three miRNAs miR-146b-5p (p = 0.032) miR-218-5p (p = 0.048) and miR-138-5p (p < 0.001) correlated to DFS in patients that had undergone adjuvant treatment. The miR-146b-5p seems to strongly modulate critical genes such as NFKBI transcriptional factor that are involved in inflammatory responses and may be a possible mediator of doxorubicin effects in sarcomas [35]. miR-146b exerts potential effects on EGFR by the NFKBI signaling pathway. EGFR was described as immunolocalized of its proteins in the cytoplasm of smooth-muscle cells in the leiomyoma and matched myometrium [8,36]. Strong interactions might be seen between miR-146b and CDKN1A, which is an important regulator of cell cycle progression at G1 and can act as a positive regulator of
senescence-like terminal proliferation arrest, but its function seems neither sufficient nor absolutely required for a treatment response to doxorubicin in tumor cells, especially soft tissue sarcoma [35].

Potential tumor suppressor miR-218-5p strongly regulates the CDKN1B, which is responsible for cell cycle progression control. This gene is widely studied in other sarcoma types such as Kaposi’s sarcoma and osteosarcoma, which exhibit aberrant CDKN1B subcellular localization [37,38]. In addition, an indirect miR-218 interaction with SMO may be seen; however, the effects of this signaling pathway are not well understood. Garcia et al. [39] evaluated the smoothened, frizzled class receptor (SMO) protein in LMS and observed that there was in unusual increased protein expression.

Although its function is uncertain, the miR-138-5p is an important IGF1R regulator. IGF1R was detected in the uterus and its expression levels were significantly higher in uterine fibroids. There is a hypothesis that the fibroids’ transformation is the main cause of LMS [3,8]. The main function of the IGF1R as a survival factor is to inhibit apoptosis, being able to increase the tumorigenic potential under some conditions, which protects them from programmed cell death when over-expressed [40]. There is a clue that when correlated with DFS, the expression of miR-146b-5p, miR-218-5p and miR-138-5p may have a role in adjuvant therapy response in US patients. Further studies are necessary to elucidate its effects in US.

New therapeutic strategies focus on recovering tumor suppressor proteins and inhibiting oncogenic ones by restoring the miRNAs that are down-regulated and silencing the miRNAs that are up-regulated [8,41]. The inhibition or delivery of miRNA may provide a highly potent means to modulate the cancer process while avoiding unwanted toxic effects in adjacent non-cancerous tissue [42]. Considering the fact that miRNAs are endogenous regulators, mechanisms that would attenuate their deregulation are likely to occur in cells, decreasing the risk of the off-target effects after their therapeutic delivery. The ability of a single miRNA to act in multiple pathways seems to decrease the possibility of developing resistance to the treatment [27].

4. Materials and Methods

4.1. Samples

This study was conducted in accordance with the Declaration of Helsinki and it was approved by the Research Ethics Committee of the Faculdade de Medicina da Universidade de Sao Paulo (FMUSP) under protocol number No. 143/11, from 2014 to 2016. Subjects gave their informed consent for inclusion before they participated in the study.

In order to compare the miRNA expression profile in different histological types of US, we selected 82 FFPE human samples (including 37 samples of LMS, 23 of CS, 18 of ESS, 2 of ADS and two benign uterine tissue myometrium). Patient samples with benign uterine tissue were only used as references (Ref) of normal gene expression; no statistical analyses were performed including them. All samples were stored at the Molecular and Structural Gynecology Laboratory of University of Sao Paulo Medical School (FMUSP). Samples were provided by the Instituto Brasileiro de Controle do Cancer, Hospital Santa Marcelina, AC Camargo Cancer Center and Disciplina de Ginecologia do Hospital das Clinicas da Faculdade de Medicina de São Paulo.

Clinical data were collected from patient charts and analyzed. The staging was performed according to the latest edition of the International Federation of Gynecology and Obstetrics (FIGO)-2009 [43]. Histological grade classification was based on nuclear polymorphism and mitotic index (Diagnostic Pathology Gynecological, 2014) [1].

4.2. MicroRNAs Expression Profile Analysis

The Qiagen miRNeasy FFPE Kit (Qiagen, Hilden, Germany) was used to extract miRNA from FFPE tissues. All samples were quantified by the spectrophotometer NanoDrop 2000 (Thermo Scientific™, Fremont, CA, USA) and cDNA synthesis (reverse transcription) was carried out using the miScript II RT Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions.
Subsequently, the quantitative real-time PCR (qRT-PCR) was carried out using the miScript SYBR® Green PCR Kit (Qiagen, Hilden, Germany) with the Human Cancer Pathway finder miRNA PCR Array MIHS-102Z-Qiagen 96 wells plate (Qiagen, Hilden, Germany), which contains 84 miRNA sequences. Levels of miRNA expression were determined by the 6 housekeeping snRNAs (SNORD-61, SNORD-68, SNORD-72, SNORD-95, SNORD-96A, and RNU6-2) for normalization, 2 extraction controls, 2 reverse transcription controls, and 2 PCR positive controls. Reactions were incubated for 15 min at 95 °C followed by 40 cycles for 15 s at 94 °C, 30 s at 55 °C, and 30 s at 70 °C in the ABI 7500 Real-Time PCR (Thermo Scientific™, Fremont, CA, USA). All data of relative expression were analyzed with the comparative cycle threshold method by ∆∆Ct [44]. The data are presented as fold regulation, which indicates expression results in a biologically meaningful form and easy to read. Values < 0 (zero) are negative (downregulated) and > 1 (one) are positive (upregulated) in relation to a reference sample. Here, we established the cut off value of ±4 to increased biological relevance and functional validation chances of these molecules. In silico analysis was performed to identify the genetic interactions network related to tumorigenesis [45] as described previously by our group [8].

4.3. Statistical Analysis

Statistical analysis was performed using GraphPad Prism version 6.07 (GraphPad Software, San Diego, CA, USA), and SPSS version 13.0 (Chicago, IL, USA) for Windows. Continuous data were analyzed for normality. Students’ t-test or ANOVA were used for between-group comparisons for parametric variables and the Mann Whitney U or Kruskal Wallis test were used for non-parametric variables.

Associations between miRNA expression and clinical pathological features were analyzed by Fisher’s exact test. Among the clinical pathological variables analyzed were age, main symptoms, oral contraceptive use, menopause, hormone replacement therapy, smoking, surgical treatment, adjuvant treatment, persistence or tumor recurrence, local or distant metastasis, degree of tumor differentiation, current status and staging. For survival curves, we used the Kaplan Meier analysis and its significance was established by log-rank-test. Survival rates were calculated based on the time or period, in months, between the date of surgery and the date of death or the date of last information. CSS was calculated in this study to exclude deaths from causes other than cancer. DFS was evaluated based on the time period, in months, between the date of surgery and the date of diagnosis of the first metastasis.

Relapse was calculated based on the time or period between the date of the anatomopathological examination and the diagnosis of recurrence of the disease over a period of more than 6 months. The persistence of the disease was considered in cases where they presented evidence of the disease already at the anatomopathological diagnosis or until, at most, 6 months from the diagnosis. Metastasis cases were considered to be those that presented distant or locoregional disease, independent of the period. Statistical significance was set at p < 0.05.

5. Conclusions

We found miR-146b-5p, miR-218-5p and miR-138-5p with higher expression in patients who underwent treatment. Concerning metastasis and recurrence, miR-210-3p was associated with ESS metastasis; miR-127-5p was related to CS relapse; and two members of the miR-29 family (29a-3p and 29b-3p) were associated with aggressive phenotypes in LMS. Besides this, the upregulation of miR-196a-5p, miR-34c-5p, miR-373-3p, miR-372-3p and downregulation of let-7b-5p were strongly associated with a lower CSS. Further studies are ongoing to determine the potential application of these molecules for the specific diagnosis, prognosis and treatment of these tumors.

Author Contributions: L.G.d.A. analyzed and organized the literature and wrote the manuscript; B.C.d.A. wrote and critically reviewed the manuscript, and performed the in silico analysis; T.G.d.A. collected the samples and data, and created the patients table; A.M.L.R. performed the statistical analysis; G.d.N.M. performed a critical review of the manuscript; F.A.S. and I.W.d.C. collected and analyzed the samples; E.C.B. performed a review of the manuscript, and searched for and organized the literature; and K.C.C. analyzed the literature, organized the data, critically reviewed the manuscript, and created the original idea.
**Funding:** This work was supported by the FAPESP (2012/23652-0) and CAPES grants.

**Conflicts of Interest:** The authors report no conflict of interest.

**References**

1. Prat, J.; Nomonde, M. Uterine sarcomas. *Int. J. Gynecol. Obstet.* 2015, 131, S105–S110. [CrossRef] [PubMed]
2. American Cancer Society. Uterine Sarcomas-UpToDate. Available online: https://www.cancer.org/cancer/uterine-sarcoma.html (accessed on 15 January 2018).
3. Almeida, T.G.; Cunha, I.W.; Maciel, G.A.R.; Baracat, E.C.; Carvalho, K.C. Clinical and molecular features of uterine sarcomas. *Med. Express* 2014, 1, 291–297. [CrossRef]
4. World Health Organization. Classification of tumours of female reproductive organs-UpToDate. Available online: http://apps.who.int (accessed on 15 January 2018).
5. Desar, I.M.E.; Ottevanger, P.B.; Benson, C.; van der Graaf, W.T.A. Systemic treatment in adult uterine sarcomas. *Crit. Rev. Oncol. Hematol.* 2018, 122, 10–20. [CrossRef] [PubMed]
6. D’Angelo, E.; Prat, J. Uterine sarcomas: A review. *Gynecol. Oncol.* 2010, 116, 131–139. [CrossRef] [PubMed]
7. Kowalewska, M.; Danska-Bidzinska, A.; Bakula-Zaleswska, E.; Bidzinski, M. Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors. *Clin. Biochem.* 2012, 45, 368–371. [CrossRef] [PubMed]
8. De Almeida, B.C.; Garcia, N.; Maffazioli, G.; dos Anjos, L.G.; Baracat, E.C.; Carvalho, K.C. Oncomirs expression profiling in uterine leiomyosarcoma cells. *Int. J. Mol. Sci.* 2018, 19, 52. [CrossRef] [PubMed]
9. Chuang, T.-D.; Ho, M.; Khorram, O. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line. *Reprod. Sci.* 2015, 22, 563–571. [CrossRef] [PubMed]
10. Parafioriti, A.; Bason, C.; Armiraglio, E.; Calciano, L.; Daolio, P.; Berardi, A.; Di Bernardo, A.; Colosimo, A.; Luksch, R.; Berardi, A. Ewing’s sarcoma: an analysis of miRNA expression profiles and target genes in paraffin-embedded primary tumor tissue. *Int. J. Mol. Sci.* 2016, 17, 656. [CrossRef] [PubMed]
11. MacFarlane, L.A.; Murphy, P.R. MicroRNA: biogenesis, function and role in cancer. *Curr. Genomics* 2010, 11, 537–561. [CrossRef] [PubMed]
12. Georgieva, B.; Milev, I.; Dimitrova, I.; Bradford, A.P.; Baev, V. Characterization of the uterine leiomyoma microRNAome by deep sequencing. *Genomics* 2012, 99, 275–281. [CrossRef] [PubMed]
13. Wang, H. Predicting microRNA biomarkers for cancer using phylogenetic tree and microarray analysis. *Int. J. Mol. Sci.* 2016, 17, 773. [CrossRef] [PubMed]
14. Romero-Cordoba, S.L.; Salido-Guadarrama, I.; Rodriguez-Dorantes, M.; Hidalgo-Miranda, A. miRNA biogenesis: biological impact in the development of cancer. *Cancer Biol. Ther.* 2014, 15, 1444–1455. [CrossRef] [PubMed]
15. Pencheva, N.; Tavazoie, S.F. Control of metastatic progression by microRNA regulatory networks. *Nat. Cell Biol.* 2013, 15, 546–554. [CrossRef] [PubMed]
16. Gadducci, A.; Cosio, S.; Romanini, A.; Genazzani, A.R. The management of patients with uterine sarcoma: a debated clinical challenge. *Crit. Rev. Oncol. Hematol.* 2008, 65, 129–142. [CrossRef] [PubMed]
17. Stofko, D.L. Undifferentiated uterine sarcoma metastatic to the brain. *Surg. Neurol. Int.* 2013, 4, 127. [CrossRef] [PubMed]
18. Zagouri, F.; Dimopoulos, A.-M.; Fotiou, S.; Kouloulas, V.; Papadimitriou, C.A. Treatment of early uterine sarcomas: disentangling adjuvant modalities. *World J. Surg. Oncol.* 2009, 7, 1–10. [CrossRef] [PubMed]
19. Felix, A.S.; Stone, R.A.; Bowser, R.; Chivukula, M.; Edwards, R.P.; Weissfeld, J.L.; Linkov, F. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrioid cancers. *Int. J. Gynecol. Cancer* 2011, 21, 877–884. [CrossRef] [PubMed]
20. Ghayemmaghami, F.; Karimi-Zarchi, M.; Gilani, M.M.; Mousavi, A.; Behtash, N.; Ghasemi, M. Uterine sarcoma: clinicopathological characteristics, treatment and outcome in Iran. *Asian Pac. J. Cancer Prev.* 2008, 9, 421–426. [PubMed]
21. Vrzic-Petronijevic, S.; Likic-Ladjevic, I.; Petronijevic, M.; Argirovic, R.; Ladjevic, N. Diagnosis and surgical therapy of uterine sarcoma. *Acta. Chir. Iugosl.* 2006, 53, 67–72. [CrossRef] [PubMed]
22. Kanthan, R.; Senger, J.-L. Uterine carcinosarcomas (malignant mixed müllerian tumours): A review with special emphasis on the controversies in management. *Obstet. Gynecol. Int.* 2011, 1–13. [CrossRef] [PubMed]

23. Reichardt, P. The treatment of uterine sarcomas. *Ann. Oncol.* 2012, 23, 151–157. [CrossRef] [PubMed]

24. Naaman, Y.; Shveiky, D.; Ben-Shachar, I.; Shushan, A.; Mejia-Gomez, J.; Benshushan, A. Uterine sarcoma: prognostic factors and treatment evaluation. *Int. Med. Assoc. J.* 2011, 13, 76–79. [PubMed]

25. Tsuyoshi, H.; Yoshida, Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. *Cancer Sci.* 2018, 109, 1743–1752. [CrossRef] [PubMed]

26. Lim, H.J.; Yang, J.-L. Regulatory roles and therapeutic potential of microRNA in sarcoma. *Crit. Rev. Oncol. Hematol.* 2016, 97, 118–130. [CrossRef] [PubMed]

27. Torres, A.; Torres, K.; Maciejewski, R.; Harvey, W.H. MicroRNAs and their role in gynecological tumors. *Med. Res. Rev.* 2011, 31, 895–923. [CrossRef] [PubMed]

28. Kowalewska, M.; Bakula-Zalewska, E.; Chechlińska, M.; Goryca, K.; Nasierowska-Guttmejer, A.; Danska-Bidzinska, A.; Bidzinski, M. microRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: a preliminary report. *Tumour Biol.* 2013, 34, 2153–2160. [CrossRef] [PubMed]

29. Guijarro, M.V.; Dahia, S.; Danielson, L.S.; Segura, M.F.; Vales-Lara, F.M.; Menendez, S.; Popiolek, D.; Mittal, K.; Wei, J.J.; Zavadil, J.; et al. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling. *Ann. J. Pathol.* 2013, 182, 2015–2027. [CrossRef] [PubMed]

30. Ravid, Y.; Formanski, M.; Smith, Y.; Reich, R.; Davidson, B. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. *Gynecol. Oncol.* 2016, 140, 512–517. [CrossRef] [PubMed]

31. Chen, B.; Liu, J.; Qu, J.; Song, Y.; Li, Y.; Pan, S. MicroRNA-25 suppresses proliferation, migration, and invasion of osteosarcoma by targeting SOX4. *Tumour Biol.* 2017, 39, e101428317703841. [CrossRef] [PubMed]

32. Shi, G.; Perle, M.A.; Mittal, K.; Chen, H.; Zou, X.; Narita, M.; Hernando, E.; Lee, P.; Wei, J.J. Let-7 repression leads to HMG2 upregulation in uterine leiomyosarcoma. *J. Cell Mol. Med.* 2009, 13, 3898–3905. [CrossRef] [PubMed]

33. Davidson, B.; Abeler, V.M.; Hellesytl, E.; Holth, A.; Shih, I.M.; Skeie-Jensen, T.; Chen, L.; Yang, Y.; Wang, T.L. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. *Gynecol. Oncol.* 2013, 128, 349–355. [CrossRef] [PubMed]

34. Devor, E.J.; DE Mik, J.N.; Ramachandran, S.; Goodheart, M.J.; Leslie, K.K. Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. *Exp. Ther. Med.* 2012, 3, 677–682. [CrossRef] [PubMed]

35. Daigeler, A.; Klein-Hitpass, L.; Chromik, M.A.; Müller, O.; Hauser, J.; Homann, H.-H.; Steinau, H.-U.; Lehnhardt, M. Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma cultures. *BMC Cancer* 2008, 8, 313. [CrossRef] [PubMed]

36. Ciarmela, P.; Islam, M.S.; Reis, F.M.; Gray, P.C.; Bloise, E.; Petraglia, F.; Vale, W.; Castellucci, M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. *Hum. Reprod. Update* 2011, 17, 772–790. [CrossRef] [PubMed]

37. Kumar, P.; Wood, C. Kaposi’s sarcoma-associated herpesvirus transactivator Rta induces cell cycle arrest in G0/G1 phase by stabilizing and promoting nuclear localization of p27kip. *J. Virol.* 2013, 87, 13226–13238. [CrossRef] [PubMed]

38. Li, Y.; Nakka, M.; Kelly, A.J.; Lau, C.C.; Krailo, M.; Barakauskas, D.A.; Hicks, J.M.; Man, T.-K. p27 is a candidate prognostic biomarker and metastatic predictor in osteosarcoma. *Cancer Res.* 2016, 76, 4002–4011. [CrossRef] [PubMed]

39. Garcia, N.; Bozzini, N.; Baiocchi, G.; da Cunha, I.W.; Maciel, G.A.; Soares, J.M.; Soares, F.A.; Baracat, E.C.; Carvalho, K.C. May Sonic Hedgehog proteins be markers for malignancy in uterine smooth muscle tumors? *Int. J. Mol. Sci.* 2015, 17, e1010428317703841. [CrossRef] [PubMed]

40. Gkioka, E.; Msaouel, P.; Philippou, A.; Vlagogiannis, N.I.; Vogkou, C.T.; Margiolis, A.; Koutsilieris, M. The role of insulin-like growth factor-1 signaling pathways in uterine leiomyoma. *In Vivo* 2015, 29, 637–649. [PubMed]

41. Berindan-Neagoe, I.; Monroig, P.D.C.; Pasculli, B.; Calin, G.A. MicroRNAome genome: A treasure for cancer diagnosis and therapy. *CA Cancer J. Clin.* 2014, 64, 311–336. [CrossRef] [PubMed]

42. Mendell, J.T.; Olson, E.N. MicroRNAs in stress signaling and human disease. *Cell* 2013, 148, 1172–1187. [CrossRef] [PubMed]
43. Prat, J. FIGO staging for uterine sarcomas. *Int. J. Gynecol. Obstet.* **2009**, *104*, 177–178. [CrossRef] [PubMed]

44. Data Analysis Center-Qiagen. Available online: https://www.qiagen.com/br/shop/genes-and-pathways/data-analysis-center-overview-page/ (accessed on 12 February 2018).

45. miR TarBase: the experimentally validated microRNA-target interactions database. Available online: http://mirtarbase.mbc.nctu.edu.tw/php/index.php (accessed on 1 February 2018).